Publications by authors named "Thomas Bohnacker"

Claim this Profile
R
Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signaling.
Lukas Bissegger, Theodora A Constantin, Erhan Keles, Luka Raguž, Isobel Barlow-Busch, Thomas Bohnacker

Chem Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K Regulatory Protein p84 Determines Mast Cell Sensitivity to Ras Inhibition-Moving Towards Cell Specific PI3K Targeting?
Julie R Jin, Elena Gogvadze, Ana R Xavier, Thomas Bohnacker, Jan Voelzmann

Front Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-(Difluoromethyl)-5-(4-((3,5)-3,5-dimethylmorpholino)-6-(()-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders.
Chiara Borsari, Erhan Keles, Denise Rageot, Andrea Treyer, Thomas Bohnacker

J Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.
Chiara Borsari, Denise Rageot, Florent Beaufils, Thomas Bohnacker, Erhan Keles

ACS Med Chem Lett· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.
Chiara Borsari, Denise Rageot, Alix Dall'Asen, Thomas Bohnacker, Anna Melone

J Med Chem· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
()-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
Denise Rageot, Thomas Bohnacker, Erhan Keles, Jacob A McPhail, Reece M Hoffmann

J Med Chem· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease.
Luca Aresu, Serena Ferraresso, Laura Marconato, Luciano Cascione, Sara Napoli, Thomas Bohnacker

Haematologica· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A class of highly selective inhibitors bind to an active state of PI3Kγ.
Gangadhara Gangadhara, Göran Dahl, Thomas Bohnacker, Rebecca Rae, Jenny Gunnarsson

Nat Chem Biol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
Denise Rageot, Thomas Bohnacker, Anna Melone, Jean-Baptiste Langlois, Chiara Borsari

J Med Chem· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
Florent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, Thomas Bohnacker, Anna Melone

J Med Chem· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
Thomas Bohnacker, Andrea E Prota, Florent Beaufils, John E Burke, Anna Melone

Nat Commun· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PKCβ phosphorylates PI3Kγ to activate it and release it from GPCR control.
Romy Walser, John E Burke, Elena Gogvadze, Thomas Bohnacker, Xuxiao Zhang

PLoS Biol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluid-phase pinocytosis of native low density lipoprotein promotes murine M-CSF differentiated macrophage foam cell formation.
Manoj K Barthwal, Joshua J Anzinger, Qing Xu, Thomas Bohnacker, Matthias P Wymann

PLoS One· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy.
Emilie Collmann, Thomas Bohnacker, Romina Marone, Janet Dawson, Markus Rehberg

J Allergy Clin Immunol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Murine bone marrow-derived macrophages differentiated with GM-CSF become foam cells by PI3Kγ-dependent fluid-phase pinocytosis of native LDL.
Joshua J Anzinger, Janet Chang, Qing Xu, Manoj K Barthwal, Thomas Bohnacker

J Lipid Res· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of the PI3K pathway increases TLR-induced TNF-α and IL-6 but reduces IL-1β production in mast cells.
Thomas Hochdörfer, Marcel Kuhny, Carolin N Zorn, Rudi W Hendriks, Bart Vanhaesebroeck, Thomas Bohnacker

Cell Signal· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110gamma.
Barbara Kurig, Aliaksei Shymanets, Thomas Bohnacker, Prajwal, Carsten Brock

Proc Natl Acad Sci U S A· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3Kgamma adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P3 pools in mast cells.
Thomas Bohnacker, Romina Marone, Emilie Collmann, Ronan Calvez, Emilio Hirsch

Sci Signal· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
Romina Marone, Dominik Erhart, Ann C Mertz, Thomas Bohnacker, Christian Schnell

Mol Cancer Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis